Clinical studies have indicated existence of an "obesity paradox" in patients with chronic heart failure (HF), i.e., reduced mortality among patients who have elevated body mass index (BMI) compared to normal weight reference groups. We aimed to investigate the relationship of BMI with all-cause and cardiovascular (CV) mortality and hospitalization in patients with chronic HF though a systematic review and meta-analysis of the literature. We searched Pub Med, CINAHL, Cochrane CENTRAL, Scopus, and EMBASE databases for studies reporting rate of total mortality, cardiac mortality and risk of hospitalization in patients with HF in various BMI categories [<20 (low); 20-24.9 (normal reference); 25-29.9 (overweight); 30-34.9 (obese); >=35 (severely obese)]. Event rates were compared using a forest plot of relative risk using a random respectively). In conclusion, risk of total mortality and CV mortality and hospitalization was highest among chronic HF patients who were underweight as defined by low BMI, whereas risk of CV mortality and hospitalization was lowest in the overweight.
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Abstract:
Clinical studies have indicated existence of an "obesity paradox" in patients with chronic heart failure (HF), i.e., reduced mortality among patients who have elevated body mass index (BMI) compared to normal weight reference groups. We aimed to investigate the relationship of BMI with all-cause and cardiovascular (CV) mortality and hospitalization in patients with chronic HF though a systematic review and meta-analysis of the literature. We searched Pub Med, CINAHL, Cochrane CENTRAL, Scopus, and EMBASE databases for studies reporting rate of total mortality, cardiac mortality and risk of hospitalization in patients with HF in various BMI categories [<20 (low); 20-24.9 (normal reference); 25-29.9 (overweight); 30-34.9 (obese); >=35 (severely obese)]. Event rates were compared using a forest plot of relative risk using a random effects model assuming inter-study heterogeneity. Two study authors [ Increasing degree of obesity failed to achieve a statistically significant effect on CV mortality respectively). In conclusion, risk of total mortality and CV mortality and hospitalization was highest among chronic HF patients who were underweight as defined by low BMI, whereas risk of CV mortality and hospitalization was lowest in the overweight.
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Introduction:
The association between BMI and all-cause and CV mortality and hospitalizations in HF is not fully understood. Due to contradictory results in various studies and lack of definitive data on prognostic value of BMI and its purposeful alteration in HF, the American College of Cardiology Foundation/American Heart Association do not provide any firm recommendations for purposeful weight loss in HF [1] . In the present study, the available evidence is systematically reviewed to examine the association between the most commonly used anthropometric measure of the degree of adiposity, namely the body BMI, with all-cause mortality and CV mortality and hospitalizations among patients with chronic HF.
METHODS

Meta-analysis was performed in accordance with the Meta-Analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [2] . A checklist of each of the MOOSE criteria and how they were handled in our study is contained in Appendix Table 1. We systematically searched PubMed, CINAHL, Cochrane CENTRAL, Scopus and Web of Science databases for all studies that reported total mortality, cardiac mortality and rate of hospitalization on the basis of BMI. All relevant combinations of the following keywords related to body mass (for example, BMI, body weight, obesity, overweight, central obesity), total mortality, CV events (for example, cardiac death, CV death, mortality), hospitalization, readmission and presence of HF (systolic HF, diastolic HF, cardiomyopathy, cardiac failure) were included for database search. The search was conducted from the inception of these databases to May 31, 2014. No language or age restrictions were applied.
Clinical studies were included if the studies met the following criteria: (i) inclusion of patients with chronic HF, (ii) reported measures of total mortality, CV mortality and/or rate of hospitalization secondary to congestive HF exacerbation according to BMI.
We could not use the standard categorization of BMI groups because of the inconsistency of across studies. Thus, we arbitrarily assigned the low BMI group when BMI was the lowest and below 20, normal BMI if it was identical or close to 20-24·9, overweight if the BMI group was identical or close to 25-29·9, obesity if it was close or identical to 30-34·9, and severe obesity if BMI was 35 or greater.
Two independent reviewers (AS, AV) screened the titles and abstracts for relevance.
Discrepancies between reviewers were discussed until consensus was reached. The manuscripts of selected titles/abstracts were reviewed for inclusion. Using the above selection criteria, two reviewers (AS, AV) independently determined the articles to be included or excluded. Data from the relevant articles were extracted using pre-defined extraction forms. Two independent reviewers (AS, AV) performed the data extraction. Any disagreements in data extraction were discussed until consensus was reached. Events for studies which reported outcome separately for patients with BMI >35 kg/m 2 was examined by removing each study sequentially to assess the degree to which the metaanalysis estimate depends on a particular study (exclusion sensitivity analysis).
RESULTS
Six studies met inclusion/exclusion criteria (N=22,807) ( Figure 1 ) [3] [4] [5] [6] [7] [8] . Follow-up duration was from 1.5 years to 4.1years. Details of the studies are summarized in Table 1 . Obese patients were younger than normal and low BMI patients on average by 4 and 7 years, respectively ( groups. There was no heterogeneity across the low BMI group (p =0.57, I 2 =0%).
The risk for hospitalization secondary to HF exacerbation was highest in the low BMI group ( Table 3 ). There was no significant heterogeneity among the low BMI (p=0.31, I 2 =17%), overweight (p=0.31, I 2 =17%) and obese groups (p=0.59, I 2 =0%),but significant heterogeneity was present across the studies in the severely obese group (p =0.005, I 2 =87%).
DISCUSSION
Our results indicate that in patients with chronic HF, the risk of all-cause and CV mortality and hospitalization was highest among those with low BMI at the end of a mean follow up period of 2.85 years and lowest in the overweight BMI group. This finding is counterintuitive and supports the presumption of a strong "obesity (or 'overweight') paradox" ( Figure 4 ).
Our results also show that, unlike less severe degrees of obesity, which seem to be associated with an obesity paradox, severe obesity is associated with quite poor overall CV outcomes, suggesting that the apparent protective effect of adiposity tends to disappear at more extreme levels of obesity. This finding is consistent with previous studies; conceivably, it could be due to deleterious effect of extreme obesity on central and peripheral hemodynamics, as well as on cardiac structure and function [9, 10, 11]. Nonetheless, Oreopoulos et al reported lower allcause mortality and CV mortality among HF patients who were overweight compared to normal weight patients [10] . However, to our knowledge, our study is the first meta-analysis to comprehensively evaluate the association between BMI, the most commonly used anthropometric parameter to assess the degree of adiposity, with all-cause and CV mortality and risk of hospitalization among patients with chronic HF. Our results demonstrate that increased
total mortality among underweight patients can be explained by the increased rates of CV mortality, as opposed to mortality from non-CV causes, including cancer. Recently, Shah et al confirmed existence of a global obesity paradox in patients with acutely decompensated HF, reporting lower 1-year mortality among patients with acute decompensated HF who have higher BMI despite heterogeneity in biochemical and clinical profiles, thus demonstrating that a lower BMI effectively defines risk of long-term mortality independently of other clinical and of biochemical indices [12] .
Several hypotheses have been proposed to explain obesity paradox in chronic HF [9, 13] .
Clearly, HF is a catabolic state and cardiac cachexia is an independent predictor of CV mortality in patients with advanced HF [14] . Patients with higher BMI also have high-energy reserve (higher body fat and lean mass), which help them to deal effectively with the high-energy requirement of HF. Alternatively, low BMI may be a marker of the severity of HF which, by itself, is the basis of outcome.
Cytokines and neuroendocrine profiles of chronic HF patients who are overweight/obese differ from those who are underweight and might play a modulating role [15] [16] [17] [18] [19] [20] . Soluble tumor necrosis factor-alpha (TNFα) receptor level has been shown to be correlated significantly with both BMI and percentage body fat, which could exert a protective role by neutralizing the circulating TNF in overweight/obese patients [15, 20] . Chronic HF patients in edematous states have higher circulating levels of bacterial lipopolysaccharide (LPS) [21] , which acts as a very strong immune activator due to its ability to release of pro inflammatory cytokines from circulating immune competent cells [17, 21] . Higher levels of circulating lipoproteins found in overweight/obese HF patients may bind and then detoxify lipopolysaccharides and have a potential anti-inflammatory effect [15, 14, 21] .
In our study obese patients were younger than normal patients and than low BMI patients, on average by 4 and 7 years, respectively. This could be due to early onset of HF among obese patients secondary to high prevalence of CAD, CV risk factors and metabolic derangement secondary to obesity [9, 10, 13, 16]. In addition, HF patients with higher BMI typically have higher arterial blood pressure than their leaner counterparts, which allow them to tolerate more cardio-protective medications, potentially at higher doses, including beta blockers, renin angiotensin aldosterone system (RAAS) inhibitors, and mineralocorticoid receptor antagonists . This could be due to failure of BMI as an anthropometric parameter to adequately assess distribution and degree of adiposity; also, BMI cannot differentiate between adipose tissue and lean body mass [25, 26] . Low BMI not only reflects low adiposity but also potentially lower body lean mass, which has been associated with poor cardiorespiratory fitness and muscular fitness, -both of which predict poor clinical outcomes [13, [27] [28] [29] .
Our study, however, also has several potential limitations. First, the prevalence of various associated comorbidities, including detailed data on various CV risk factors and duration and severity of HF and etiology of HF among various categories of BMI, was not reported, and, hence, could not be analyzed in the present meta-analysis. Thus, it remains unclear whether our findings can be attributed to more advanced disease in patients with low BMI. Studies included in our analysis have not taken into consideration any unintentional weight loss among patients; therefore, we cannot rule out the possibility of residual confounding effects in our study. Further,
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9 our study did not evaluate the impact of targeted weight reduction in various BMI categories, thus it is not clear if targeted weight loss in morbidly obese patient of weight gain in underweight patients is beneficial or not. These issues need to be addressed in randomized control trial before making any specific recommendations. Second, higher levels of physical activities has been shown to improve cardiovascular risk profile and poor cardiorespiratory fitness is a strongly associated with adverse clinical outcomes in chronic HF patients [30, 31] . However, as studies included in our meta-analysis did not report the data on physical activities on patients or its impact on clinical outcome, we were unable to assess this important question in our present study. Third, not all studies included in our analysis classified their patients using the standard BMI categories. In addition, parameters of central adiposity, estimation of body fat and lean body mass (or non-fat mass) were not provided in the studies included in our analysis, precluding assessment of the relationship between these important body composition parameters with various end points. Fourth, average follow up in our study was 2.85 years, which might not be long enough to evaluate the negative impact of obesity on various clinical end points. 
Problem definition
Clinical studies have indicated existence of an obesity paradox in patients with chronic heart failure (HF) i.e. reduced mortality among patients who have elevated body mass index (BMI) compared to normal weight reference groups. We aim to investigate the relationship of body mass index (BMI) with total mortality, cardiac mortality and risk of hospitalization in patients with chronic HF.
√
Hypothesis statement
Lower BMI is associated with worse clinical outcome in patients with chronic HF.
√ Description of study outcomes Total mortality, cardiac mortality and risk of hospitalization √ Type of study designs used We include various retrospective and prospective comparative studies reporting total mortality, cardiac mortality and the risk of hospitalization among various BMI categories in patients with chronic HF.
√
Study population
We placed no restriction. No language restriction was applied while searching various databases. Google translation was used to article published in language other than English.
√
Method of handling abstracts and unpublished studies
We contacted few authors for unpublished studies.
√
Description of any contact with authors
We contacted few authors who have reported few but not all outcome of interest.
Reporting of methods should include
√ Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested Detailed inclusion and exclusion criteria were described in the methods section. Table 1 .
√
Results of sensitivity testing
Results. The influence of individual studies was examined by removing each study at a time to assess the degree to which meta-analysis estimate depends on a particular study (exclusion sensitivity analysis). 
√
Justification for exclusion
We excluded studies that had not reported total mortality, cardiac mortality and the risk of hospitalization among various BMI categories in patients with chronic HF.
√
Assessment of quality of included studies
We discussed the results of the sensitivity and heterogeneity analyses
Reporting of conclusions should include
√
Consideration of alternative explanations for observed results
We discussed the potential failure of BMI as an anthropometric parameter to adequately assess degree and distribution of adiposity. We also discussed other potential biases including the potential unmeasured confounders that may have caused residual confounding.
√ Generalization of the conclusions Risk of total mortality, cardiac mortality and hospitalization was highest among chronic heart failure patients who were underweight patients as defined by low BMI √ Guidelines for future research We recommend future studies to -Investigate this association and explore potential underlying mechanisms -Investigate other anthropometric parameters like waist to hip ratio, waist circumference to assess degree of adiposity and assessing prognosis in HF patients.
√
Disclosure of funding source None
